BioStock: Xintela’s CEO sees potential in difficult-to-heal wounds

Difficult-to-heal wounds are a painful and costly problem that Xintela has chosen to address. This year, the company will start a phase I/II study with the stem cell product XSTEM in patients with difficult-to-heal leg ulcers. The market potential and medical needs in this area are extensive, says CEO Evy Lundgren-Åkerlund, whom BioStock has interviewed.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/04/xintelas-ceo-sees-potential-in-difficult-to-heal-wounds/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se